Manari Antonio, Costa Elena, Scivales Alessandro, Ponzi Patrizia, Di Stasi Francesca, Guiducci Vincenzo, Pignatelli Gianluca, Giacometti Paola
Department of Interventional Cardiology, 'Santa Maria Nuova' Hospital, Reggio Emilia, Italy.
J Cardiovasc Med (Hagerstown). 2007 Oct;8(10):792-8. doi: 10.2459/JCM.0b013e328012c1b6.
Growing interest in the use of drug-eluting stents (DESs) in coronary angioplasty has prompted the Healthcare Agency of the Emilia Romagna Region to draw up recommendations for their appropriate clinical use in high-risk patients. Since the adoption of any new technology necessitates economic appraisal, we analysed the resource consumption of the various types of angioplasty procedures and the impact on the budget of a cardiology department.
A retrospective economic appraisal was carried out on the coronary angioplasty procedures performed in 2004 in the Department of Interventional Cardiology of Reggio Emilia. On the basis of the principles of activity-based costing, detailed hospital costs were estimated for each procedure and compared with the relevant diagnosis-related group (DRG) reimbursement.
In 2004, the Reggio Emilia hospital performed 806 angioplasty procedures for a total expenditure of euro 5,176,268. These were 93 plain old balloon angioplasty procedures (euro 487,329), 401 procedures with bare-metal stents (euro 2,380,071), 249 procedures with DESs (euro 1,827,386) and 63 mixed procedures (euro 481,480). Reimbursements amounted to euro 5,816,748 (11% from plain old balloon angioplasty, 50% from bare-metal stent, 31% from DES and 8% from mixed procedures) with a positive margin of about euro 680,480 between costs incurred and reimbursements obtained, even if the reimbursement for DES and mixed procedures was not covering all the incurred costs.
Analysis of the case-mix of procedures revealed that an overall positive margin between costs and DRG reimbursements was achieved. It therefore emerges that adherence to the indications of the Healthcare Agency of the Emilia Romagna Region for the appropriate clinical use of DESs is economically sustainable from the hospital enterprise point of view, although the DRG reimbursements are not able to differentiate among resource consumptions owing to the adoption of innovative technologies.
对药物洗脱支架(DES)在冠状动脉血管成形术中应用的兴趣与日俱增,这促使艾米利亚-罗马涅大区医疗保健机构制定了在高危患者中合理临床使用DES的建议。由于采用任何新技术都需要进行经济评估,我们分析了各类血管成形术的资源消耗情况以及对心内科预算的影响。
对2004年雷焦艾米利亚介入心脏病科进行的冠状动脉血管成形术进行回顾性经济评估。基于作业成本法的原则,估算了每个手术的详细医院成本,并与相关诊断相关分组(DRG)报销费用进行比较。
2004年,雷焦艾米利亚医院进行了806例血管成形术,总支出为5,176,268欧元。其中93例为普通球囊血管成形术(487,329欧元),401例使用裸金属支架(2,380,071欧元),249例使用DES(1,827,386欧元),63例为混合手术(481,480欧元)。报销金额为5,816,748欧元(普通球囊血管成形术占11%,裸金属支架占50%,DES占31%,混合手术占8%),即使DES和混合手术的报销未能涵盖所有发生的成本,成本与报销之间仍有大约680,480欧元的正利润。
对手术病例组合的分析表明,成本与DRG报销之间总体上实现了正利润。因此可以看出,从医院企业的角度来看,遵循艾米利亚-罗马涅大区医疗保健机构关于DES合理临床使用的指征在经济上是可持续的,尽管由于采用了创新技术,DRG报销无法区分资源消耗情况。